Ọrịa na isi na olu cancer na-ewuru a groundbreaking ọhụrụ ọgwụgwọ na-agụnye apostle ha dịghịzi usoro ibu agha ọrịa.
Ikpe, na National Institute for Health Research Biomedical Research center na Guy si na St Thomas 'NHS ntọala ntụkwasị obi na Eze College London, -agụnye genetically modifying ọrịa mkpụrụ ndụ ọbara ọcha, ya mere ha na-aghọta na ọgụ ngwọta.
Mkpụrụ ndụ ọbara ọcha nke dịghịzi usoro na-ndammana onwem iji kpochapụ mkpụrụ ndụ - karịsịa ndị butere ọrịa - na ekwesịghị n'ebe, ma mgbe ụfọdụ, chọrọ enyemaka ịmata na agha cancer mkpụrụ ndụ.
Iji a ọbara sample, na BRC otu na-emeso mkpụrụ ndụ ọbara ọcha na laabu na a na-adịghị njọ virus na-ewebata ọhụrụ abụọ mkpụrụ ndụ ihe nketa. The mbụ site n'usoro na-eme ka ọ dịkwuo mfe na-eto eto na mkpụrụ ndụ mgbe ha na laabu mgbe nke abụọ na-enyere ndị mkpụrụ ndụ ọbara ọcha na-aghọta na ọgụ ngwọta.
Isi investigator Dr John Maher kwuru: "N'ihe ka ọtụtụ ọrịa cancer, metastasis, mgbasa nke a ọrịa site na nke ozu ebe ọ malitere ọzọ kpọmkwem ejikọrọ, bụ commonest akpata ọnwụ. Otú ọ dị, isi na olu cancer na-agbapụ iche na obodo mgbasa ma ọ bụ nlọghachite nke ọrịa akaụntụ n'ihi na ọtụtụ nhụjuanya na ọnwụ. Nke a pụtara na etuto ahụ wee dị inoperable na-adịghị ịda mbà omume omenala agwọ ọrịa dị ka anara ọgwụ ma ọ bụ Radiotherapy. "
The ọgwụgwọ a na-akpọ a CAR T-cell and takes two weeks to produce. To maximise its safety and effectiveness the team is injecting the CAR T-cells directly into the tumour. CAR T-cell treatment has proven effective in some forms of leukaemia but the hope is that it can be developed further to benefit patients with so-called “solid cancers”, which form a discrete tumour mass, such as head and neck cancer.
Maher said success could have “significant implications for other solid cancers, especially those that spread within a natural space in the body, such as ovarian cancer (lining of the abdomen) or mesothelioma (lining of the lungs). In that setting, it may be possible to inject the CAR T-cells from the patient directly into the cavity, to localise the treatment where it is needed most”.
During the phase 1 trial, which aims to test the treatment’s safety and effectiveness, patients enrolled in groups will successively receive a higher number of cells to establish safe dosage, provided it does not produce significant side-effects. If it is successful, the treatment will need to be tested in larger numbers of patients to establish how effective it is at combating the cancer.
Dr Stephen Caddick, director of innovations at the Wellcome Trust, which co-funded the trial, kwuru: “By precision engineering immune cells to recognise and destroy tumours, researchers are hopeful that they will be able to improve the prospects for patients who have, until now, faced very limited treatment options.”
guardian.co.uk © Guardian News & Media Limited 2010